title: Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
authors.affiliation: Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: B Nhi
authors.initials: BN
authors.lastname: Beasley
authors.forename: Ellis F
authors.initials: EF
authors.lastname: Unger
authors.forename: Robert
authors.initials: R
authors.lastname: Temple
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000069604:Dabigatran; D017277:Drug Approval; D004617:Embolism / Q000517:prevention & control*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D020521:Stroke / Q000517:prevention & control*; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran